Biofrontera Bioscience GmbH is based in Leverkusen and is registered at the Local Court of Cologne under HRB 49856. In the 2023 financial year the company reported revenue of 10,859 TEUR, of which 10,157 TEUR arose from a licensing agreement with Biofrontera Pharma GmbH. Major expenses included material costs for clinical studies of 2,603 TEUR and FDA fees of 399 TEUR. Biofrontera AG is the sole shareholder and finances the company; as of the balance sheet date there was an uncovered deficit of 33,286 TEUR, secured by a shareholder subordination declaration of 37,000 TEUR.
die Entwicklung und der Vertrieb von Pharmazeutika sowie der Vertrieb von Medizinprodukten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 49856 (as of 27 October 2026)
| Name | Type | City |
|---|---|---|
| Montserrat Foguet Roca | Geschäftsführer(in) | Leverkusen |
| Maria de la Huerta Martinez | Geschäftsführer(in) | Madrid |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 49856 (as of 27 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 04.10.2025 | Business Purpose Update | die Entwicklung und der Vertrieb von Pharmazeutika sowie der Vertrieb von Medizinprodukten. |
| 16.04.2010 | Business Address Registered | Hemmelrather Weg 201, 51377 Leverkusen |
| 22.12.2005 | Company Name Change | Biofrontera Bioscience GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 12.06.2003 | Share Capital Set | — | 26.000 € |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 49856 (as of 27 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €7,217,658 | -€1,323,969 | €39,021,746 | — |
| 2023 | €10,858,947 | €1,711,960 | €35,713,895 | — |
| 2022 | €6,257,608 | -€577,109 | €36,957,667 | — |
| 2021 | €6,257,608 | -€8,063,258 | €38,171,312 | — |
| 2020 | €7,239,508 | €114,213 | €29,587,431 | — |
| 2019 | €8,290,877 | -€2,151,804 | €32,637,047 | — |
| 2018 | €4,510,461 | -€733,175 | €30,328,586 | — |
| 2017 | €3,930,411 | -€1,290,926 | €28,677,945 | — |
| 2016 | ≤ €12M1 | -€888,784 | €26,736,885 | — |
| 2015 | ≤ €12M1 | -€6,580,491 | €25,312,524 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 49856 (as of 27 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €1,299,666 | 31.1% |
| Material Costs | €1,784,267 | 42.6% |
| Depreciation | €38,153 | 0.9% |
| Interest & Similar | €1,062,872 | 25.4% |
